Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 5/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29821598 | 0.87 | CES2 (0.38) | ALDH1A1HPGDSMN1; SMN2PDE3BPDE3A | |
| SCHEMBL3764991 | 0.87 | CES2 (0.38) | ALDH1A1HPGDSMN1; SMN2PDE3BPDE3A | |
| SCHEMBL2073770 | 0.87 | PDE3B (0.39) | ALDH1A1HPGDSMN1; SMN2PDE3BPDE3A | |
| SCHEMBL12221612 | 0.83 | SMN1; SMN2 (0.52) | ALDH1A1HPGDSMN1; SMN2ERN1HSP90AA1 | |
| SCHEMBL25159879 | 0.82 | ENPP2 (0.42) | ALDH1A1HPGDSMN1; SMN2PDE3BPDE3A | |
| SCHEMBL29957193 | 0.81 | KMT2A (0.51) | ALDH1A1HPGDSMN1; SMN2ERN1MAPT | |
| SCHEMBL3759687 | 0.81 | KMT2A (0.51) | ALDH1A1HPGDSMN1; SMN2ERN1MAPT | |
| SCHEMBL29902315 | 0.80 | ERN1 (0.48) | ALDH1A1HPGDSMN1; SMN2ERN1KMT2A | |
| SCHEMBL177412 | 0.80 | ERN1 (0.48) | ALDH1A1HPGDSMN1; SMN2ERN1KMT2A | |
| SCHEMBL29955223 | 0.79 | SMN1; SMN2 (0.41) | ALDH1A1HPGDSMN1; SMN2PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | ALDH1A1 4339/4885HPGD 2790/4885SMN1; SMN2 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.